Extracorporeal blood oxygenation and ozonation (EBOO): A controlled trial in patients with peripheral artery disease

International Journal of Artificial Organs

Volumn 28, Issue 10, 2005, Pages 1039-1050

  Di Paolo, Nicola ^a   Bocci, V ^b   Salvo, D P ^a   Palasciano, F ^b   Biagioli, M ^c   Meini, S ^c   Galli, F ^c   Ciari, I ^b   Maccari, F ^b   Cappelletti, F ^a   Di Paolo, M ^d   Gaggiotti, E ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Extracorporeal circulation; Ozone therapy; Peripheral arterial disease

Indexed keywords

BLOOD; DERMATOLOGY; DISEASE CONTROL; DISEASES; OZONIZATION; PATIENT MONITORING;

CLINICAL TRIAL; CONTROLLED TRIAL; EXTRACORPOREAL CIRCULATION; OZONE THERAPY; PERIPHERAL ARTERIAL DISEASE; PERIPHERAL ARTERY DISEASE; QUALITY OF LIFE; SKIN LESION; VASCULARIZATION; WELL BEING;

OZONE;

ENDOPROST 50; OZONE; PROSTACYCLIN;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; BLOOD OXYGENATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; LEG DISEASE; MALE; MEDICAL DOCUMENTATION; MEDICAL PARAMETERS; OZONATION; PAIN; PERIPHERAL VASCULAR DISEASE; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DEFECT; VASCULARIZATION; WELLBEING;

EID: 29244436353     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502801012     Document Type: Article

References (64)

1. Bocci V. Oxygen-ozone therapy. A critical evaluation. Dordrecht: Kluwer Academic Publishers; 2002.
2. Viebahn R. The use of ozone in medicine. 2nd ed. Heidelberg: Karl F. Haug Verlag; 1994. p 1-178.
3. Leon OS, Menendez S, Merino N, Castillo R, Sam S, Perez L, Cruz E, Bocci V. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Imflamm 1998; 7: 289-94.
4. Baysan A, Whiley RA, Lynch E. Antimicrobial effect of a novel ozone-generating device on micro-organism associated with primary root carious lesions in vitro. Caries Res 2000; 34: 498-501.
5. Bocci V. Ozonization of blood for the therapy of viral disease and immunodeficiencies. A hypothesis. Med Hypotheses 1992; 39: 30-4.
6. De Groote D. Direct stimulation of cytokine (IL-1β, TNF-α, IL-6, IL-2, IFN -γ and GM-CFS) in whole blood. I. Comparison with isolate PBMC stimulation. Cytokine 1992; 4: 239-48.
7. Schwarz KB. Oxidative stress during viral infection: A review. Free Radic Biol Med 1996; 21: 641-9.
8. Los M, Droge W, Stricker K, et al. Hydrogen peroxide as a potent activator of T-lymphocyte functions. Eur J Immunol 1995; 25: 159-65.
9. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Rossi R, Cardaioli E, Di Simplicio P. Studies on the biological effects of ozone: 4. Cytochine production and glutathione levels in human erythrocytes. J Biol Regul Homeost Agent 1998; 12: 67-75.
10. Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factors (TNF-α) on human leucocytes. Lymphokine Cytokine Res 1991; 10: 409-12.
11. Tylicki L, Nieweglowski T, Biedunkiewicz B, Chamienia A, Debska-Slizien A. The influence of ozonated autohemotherapy on oxidative stress in hemodialysed patients with atherosclerotic ischemia of lower limbs. Int J Artif Organs 2003; 26: 297-300.
12. Valdes RA, Cepero MS, Moraleda GM, Pozo LJ. Ozone therapy in the advanced stages of arteriosclerosis obliterans. Angiologia 1993; 45: 146-8.
13. Viebahn R. Physikalisch-chemische Grundlagen der Ozon-therapie. Erfahrungsheilkunde 1975; 5: 129.
14. Bocci V. Ozone as bioregulator: Pharmacology and toxicology of ozone-terapy today. J Biol Regul Homeost Agent 1996; 10: 31-53.
15. Wainer DD, Burton GW, Ingold KU, Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. FEBS Lett 1985; 187: 33-7.
16. Torre-Amione G, Sectier F, Radovancevic B, Young J. Effect of a novel immune modulation therapy in patients with advanced chronic heart failure. J Am Coll Cardiol 2004; 44: 1181-6.
17. Romero VA, Bianco GR, Menendez CS, Gomez MM, Ley PG. Arteriosclerosis obliterans and ozone therapy. Its administration by different routes. Angiologia 1993; 45: 177-9.
18. Bocci V. Is ozonotherapy therapeutic? Perspect Biol Med 1998; 42: 141-3.
19. Hatch GE. Commentary on "Cellular, biochemical and functional effects of ozone: New research and perspectives on ozone health effects". Toxicology Letters 1990; 51: 119-20.
20. Tylicki L, Rutkowski B. Ozone therapy seems to be safe, but is it really clinically effective? Inter J Artif Organs 2004; 27: 731-2.
21. Bocci V. Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993; 12: 121-6.
22. De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med 2005 11: 363-7.
23. Hernandez Rosales FA, Calunga Fernandez JL, Turrent Figueras J, Menendez Cepero S, Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. Arch Med Res 2005; 36: 549-54.
24. Biedunkiewicz B, Tylicki L, Nieweglowski T, Burakowski S, Rutkowski B. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: An oxygen-controlled study. Int J Artif Organs 2004; 27: 29-34.
25. Bocci V, Paulesu L. Studies on the biological effects of ozone: 1. Induction of interferon gamma on human leucocytes. Haematologica 1990; 75: 510-5.
26. Di Paolo N, Bocci V, Garosi G, Borrelli E, Bravi A, et al. Extracorporeal Blood Oxygenation and Ozonation (EBOO). Preliminary report. Int J Artif Organs 2000; 23: 131-41.
27. Bocci V, Di Paolo N, Garosi G, Aldinucci C, Borrelli E, Valacchi G, Cappelli F, Guerri L, Gavioli G, Corradeschi F, Rossi R, Giannerini F, Di Simplicio P. Ozonation of blood during extracorporeal circulation. I. Rationale, methodology and preliminary studies. Int J Artif Organs 1999; 22: 645-51.
28. Bocci V, Di Paolo N, Borrelli E, Larini A, Cappelletti F: Ozonation of blood during extracorporeal circulation II. Comparative analysis of several oxygenators-ozonators and selection of one type. Int J Artif Organs 2001; 24: 890-7.
29. Di Paolo N, Bocci V, Cappelletti F, Petrini G, Gaggiotti E. Necrotizing fascitiis successfully treated with EBOO (Extracorporeal Blood Oxygenation and Ozonization). Int J Artif Organs 2002; 25: 1194-8.
30. Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy (Editorial). Int J Artif Organs 2004; 27: 168-75.
31. Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy and clinical efficacy (Letter to the Editor). Int J Artif Organs 2004; 27: 733.
32. Bocci V, Di Paolo N. Oxygenation-ozonization of blood during extracorporeal circulation (EBOO) Part III: A new medical approach. Ozone Science and Engineering 2004; 26: 195-205.
33. Di Paolo N, Bocci V. EBOO (Extracorporeal Blood Oxygenation and Ozonization). Cosenza: Bios Ed; 2003.
34. Di Paolo N, Gaggiotti E, Galli F. Extracorporeal blood oxygenation and ozonation: Clinical and biological implication in ozone therapy (Review). Redox Report 2005; 10: 121-30.
35. Ware JE Jr, Keller SD, Gandek B, Brazier JE, Sullivan M. Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. Int J Technol Assess Health Care 1995; 11: 525-51.
36. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 223: 302-10.
37. Martinez-Sanchez G, Al-Dalain SM, Menendez S, Re L, Giuliani A, Candelario-Jalil E, Alvarez H, Fernandez-Montequin JI, Leon OS. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005; (Epub ahead of print).
38. Daschner FD. Hepatitis C and human immunodeficiency virus infection following ozone autohaemotherapy. Eur J Clin Microbiol Infect Dis 1997; 8: 620.
39. Bocci V. Autohaemotherapy after treatment of blood with ozone. A reappraisal. J Int Med Res 1994; 22: 131-44.
40. Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A, Giunta L, Mascolo L, Tirelli A, Coppola L. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol 2001; 80: 745-8.
41. Carpendale MT, Freeberg JK. Ozone inactivates HIV at noncytotoxic concentrations. Antiviral Res 1991; 16: 281-92.
42. Garber GE, Cameron DW, Hawley-Foss N, Greenway D, Shannon ME. The use of ozone-treated blood in the therapy of HIV infection and immune disease: A pilot study of safety and efficacy. AIDS 1991; 5: 981-4.
43. Bocci V. Ozone as bioregulator: Pharmacology and toxicology of ozone-terapy today. J Biol Regul Homeost Agents 1996; 10: 31-53.
44. Bocci V. Ozonetherapy may act as a biological response modifier in cancer. Forsch Komplementarmed 1998; 5: 54-60.
45. Bocci V, Luzzi E, Corradeschi F, Silvestri S. Studies on the biological effects of ozone: 6. Production and transforming growth factor Beta by human blood after ozone treatment. J Biol Regul Homeost Agents 1994; 8: 108-12.
46. Bocci V. Biological and clinical effects of ozone. Has ozonotherapy a future in medicine? Br J Biomed Sci 1999a; 56: 270-9.
47. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm 1998; 7: 313-7.
48. Arsalane K, Gosset P, Vanhee DI. Ozone stimulates synthesis of inflammatory cytokines by alveolar macrophages in vitro. Amer J Respir Cell Mol Biol 1995; 13: 60-8.
49. Coppola L, Lettieri B, Cozzolino D, Luongo C, Sammartino A, Guastafierro S, Coppola A, Mastrolorenzo L, Gombos G. Ozonized autohaemotrasfusion and fibrinolytic balance in peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2002; 13: 671-81.
50. Rilling S, Viebahn R. The use of ozone in medicine. 2nd ed. Heidelberg: Karl F. Haug Verlag; 1987. p 7, 187.
51. Sweet F, Kao MS, Lee S. Ozone selectively inhibits growth of human cancer cells. Science 1980; 209: 931-3.
52. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95: 3C-8C.
53. Hirsch WR, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary cases. JAMA 2001; 286: 1317-24.
54. Klugherz B, Molher ER. Current and emerging therapies for lower extremity peripheral arterial disease. Acc Curr J Rev 2001; 81: 602-9.
55. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Eng J Med 2001; 344: 1608-21.
56. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. J Thromb Haemost 2005; 3: 1628-37.
57. Ho V, Wirthlin D, Yun H, Allison J. Physician supply, treatment, and amputation rates for peripheral arterial disease. J Vasc Surg 2005; 42: 81-7.
58. Plitter MH, Ernst E. Complementary therapies for peripheral arterial disease: Systematic review. Atherosclerosis 2005; 181: 1-7.
59. Bachoo P. Peripheral arterial disease. Clin Evid 2004; 12: 144-58.
60. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg 2000; 20: 358-62.
61. Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. Eur Rev Med Pharmacol Sci 1998; 2: 53-9.
62. Drug treatment strategies for peripheral obliterative arteriopathy. Drugs 1998; 56 (suppl 3): S17-23.
63. Melian EB, Goa KL. Beraprost: A review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002; 62: 107-33.
64. Ruggenenti P, Viganò G, Mecca G, Cassina G, Remuzzi G. Failure of prostacyclin to improbe arterial disease in dialysis patients. Nephron 1990; 54: 93-4.